Silencing of Transforming Growth Factor-β1 <i>In situ</i> by RNA Interference for Breast Cancer: Implications for Proliferation and Migration <i>In vitro</i> and Metastasis <i>In vivo</i>

Abstract

Therapies targeting the TGF-beta signaling pathway may be more effective in late-stage disease to prevent organ metastasis but not primary tumor formation and may be combined with other tumor-targeted therapies normally limited by increased circulating TGF-beta levels.